Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
Larotrectinib achieved extremely durable responses, extended survival and had a favourable safety profile in treatment-naïve patients with TRK fusion cancers, supporting its use in this population. Elective discontinuation of larotrectinib may be feasible in selected paediatric patients, with response achievable after restarting larotrectinib in cases of recurrent off-therapy disease.
Authors
- C.E. Mussi
- Ray McDermott (ORCID: https://orcid.org/0000-0002-8952-4315)
- Vadim Bernard-Gauthier
- Esther De La Cuesta (ORCID: https://orcid.org/0000-0001-7072-1493)
- Makoto Tahara (ORCID: https://orcid.org/0000-0001-9035-3106)
- Lifei Shen
- Miranda P. Dierselhuis
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Daniel H. Orbach (ORCID: https://orcid.org/0000-0002-2520-139X)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Theodore Willis Laetsch (ORCID: https://orcid.org/0000-0002-8497-3138)
- Rui‐Hua Xu (ORCID: https://orcid.org/0000-0001-9771-8534)
- Nikolaus Neu
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Children's Hospital of Philadelphia (US)
- The University of Texas MD Anderson Cancer Center (US)
- Bayer (United States) (US)
- Université de Bordeaux (FR)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Cornell University (US)
- Université Paris Sciences et Lettres (FR)
- Peking University Cancer Hospital (CN)
- Cancer Trials Ireland (IE)
- Bayer (Canada) (CA)
- St. Vincent's University Hospital (IE)
- Bayer (Italy) (IT)
- Princess Máxima Center (NL)
- Institut Bergonié (FR)
- National Cancer Center Hospital East (JP)
- Sun Yat-sen University Cancer Center (CN)
- University of Pennsylvania (US)
- Philadelphia University (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105110
- Citations
- 5
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 10.03